

Financial Tearsheet

Company Overview

Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Jun 30, 2020	Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Jun 02, 2020	Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors
Apr 28, 2020	Kannalife, Inc. CEO Op-Ed Featured in Green Entrepreneur Magazine's Latest Edition
Apr 16, 2020	Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain
Apr 14, 2020	Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD
















IR Contacts

Investor Relations Investor Relations Firm CORE IR 377 Oak Street Garden City, NY 11530 (516) 222-2285 www.coreir.com Contact: John Marco Johnm@coreir.com	Transfer Agent Securities Transfer Corp. 2901 Dallas Parkway, Suite 380, Plano, TX 75093 (469) 633-0101 www.stctransfer.com
Auditors DBB McKennon 12790 El Camino Real #130 San Diego, CA 92130 (858) 217-4035 www.dbbmckennon.com	Corporate Counsel Procopio, Cory, Hargreaves & Savitch LLP. 525 B Street, Suite 2200 San Diego, CA 92101 (619) 238-1900 www.procopio.com

Stock Performance

Today's Open	0.9040
Volume	2,745
Day Range	0.8110 - 0.9040
52 Week Range	0.3420 - 6.9000
Bid/Ask	0.0000 / 0.8700
Bid/Ask Size	0 X 2,500
Previous Close	0.8500
Market Cap	63.11 million
Shares Outstanding	74.25 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.040500
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▼	Form Type	Description	View
Aug 12, 2020	10-Q	Quarterly report	  
May 14, 2020	10-Q	Quarterly report	  
Mar 30, 2020	10-K	Annual report	  
Nov 13, 2019	10-Q	Quarterly report	  
Aug 13, 2019	10-Q	Quarterly report	  

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director